CN118891066A - 用于癌症治疗和成像的复合物 - Google Patents

用于癌症治疗和成像的复合物 Download PDF

Info

Publication number
CN118891066A
CN118891066A CN202380027967.6A CN202380027967A CN118891066A CN 118891066 A CN118891066 A CN 118891066A CN 202380027967 A CN202380027967 A CN 202380027967A CN 118891066 A CN118891066 A CN 118891066A
Authority
CN
China
Prior art keywords
radionuclide
complex
pharmaceutical composition
psma
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380027967.6A
Other languages
English (en)
Chinese (zh)
Inventor
罗伊·H·拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciencons AS
Original Assignee
Sciencons AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciencons AS filed Critical Sciencons AS
Publication of CN118891066A publication Critical patent/CN118891066A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
CN202380027967.6A 2022-01-21 2023-01-20 用于癌症治疗和成像的复合物 Pending CN118891066A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22152725.2 2022-01-21
EP22152725 2022-01-21
PCT/EP2023/051355 WO2023139203A1 (en) 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging

Publications (1)

Publication Number Publication Date
CN118891066A true CN118891066A (zh) 2024-11-01

Family

ID=79927204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380027967.6A Pending CN118891066A (zh) 2022-01-21 2023-01-20 用于癌症治疗和成像的复合物

Country Status (6)

Country Link
US (1) US20250099631A1 (https=)
EP (1) EP4466032A1 (https=)
JP (1) JP2025503096A (https=)
CN (1) CN118891066A (https=)
AU (1) AU2023208408A1 (https=)
WO (1) WO2023139203A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297877A1 (en) * 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers

Also Published As

Publication number Publication date
WO2023139203A1 (en) 2023-07-27
JP2025503096A (ja) 2025-01-30
AU2023208408A1 (en) 2024-08-01
US20250099631A1 (en) 2025-03-27
EP4466032A1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
Trump et al. Synthesis and evaluation of 99mTc (CO) 3-DTPA-folate as a folate-receptor-targeted radiopharmaceutical
Severin et al. The impact of weakly bound 89Zr on preclinical studies: non-specific accumulation in solid tumors and aspergillus infection
Ortiz-Arzate et al. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c (RGDfK)] 2 for breast cancer imaging
WO2023097329A1 (en) Radiopharmaceutical treatment methods and use
Komal et al. Localization mechanisms of radiopharmaceuticals
Zhang et al. First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors
CN118891066A (zh) 用于癌症治疗和成像的复合物
US20220080059A1 (en) RADIOLABELING AND FORMULATION FOR SCALE UP OF 64Cu-DOTATATE
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
Orsini et al. Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications
Leitha Nuclear medicine: proof of principle for targeted drugs in diagnosis and therapy
Cornelissen et al. Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor
US20240131206A1 (en) Peptide receptor radionuclide therapy
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
Das et al. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: A comparison with ‘in-situ’preparation at hospital radiopharmacy
Yu et al. Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging
JP4863345B2 (ja) 心筋用放射性画像診断剤又は放射性治療薬
Bundschuh et al. Enrico Michler1· David Kästner1· Marc Pretze1· Holger Hartmann1· Robert Freudenberg1· Michael K. Schultz2·
WO2004071505A2 (en) Radiolabelled d-amino acids for use in diagnosis with spect and pet and systemic radionuclide therapy
Ercan et al. Labelling and evaluation of 99Tcm-cyclophosphamide for tumour visualization
Bruland et al. Targeted radionuclide therapy in bone cancer
Bari et al. Radiopharmaceuticals: A New Era in Cancer Therapy–Light on Initial Findings on Animal Model
Sarwer et al. Localization Mechanisms of
TW202313120A (zh) 膽囊收縮素b受體靶向複合體及其造影劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination